Respiratory Distress Syndrome, Infant (IRDS)

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Respiratory Distress Syndrome, Infant

MalaCards integrated aliases for Respiratory Distress Syndrome, Infant:

Name: Respiratory Distress Syndrome, Infant 20
Hyaline Membrane Disease 20 71
Rds - Infants 20 71
Infantile Respiratory Distress Syndrome 20
Neonatal Respiratory Distress Syndrome 20
Respiratory Distress Syndrome, Newborn 71
Infantile Respiratory Distress 6
Irds 20
Nrds 20


External Ids:

UMLS 71 C0020192 C0035220 C2931829

Summaries for Respiratory Distress Syndrome, Infant

MalaCards based summary : Respiratory Distress Syndrome, Infant, also known as hyaline membrane disease, is related to respiratory distress syndrome in premature infants and newborn respiratory distress syndrome, and has symptoms including dyspnea, hemoptysis and apnea. An important gene associated with Respiratory Distress Syndrome, Infant is ABCA3 (ATP Binding Cassette Subfamily A Member 3), and among its related pathways/superpathways is Surfactant metabolism. The drugs Beractant and Zinc have been mentioned in the context of this disorder. Affiliated tissues include lung, bone marrow and bone, and related phenotype is growth/size/body region.

Related Diseases for Respiratory Distress Syndrome, Infant

Diseases related to Respiratory Distress Syndrome, Infant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 respiratory distress syndrome in premature infants 32.8 SFTPC ABCA3
2 newborn respiratory distress syndrome 31.2 SFTPC GJB2 BRAF ABCC8 ABCA3
3 interstitial emphysema 30.8 SFTPC ABCA3
4 surfactant dysfunction 30.0 SFTPC ABCA3
5 pulmonary immaturity 29.9 SFTPC ABCA3
6 neonatal respiratory failure 29.8 SFTPC ABCA3
7 adult respiratory distress syndrome 29.4 SFTPC GJB2 ABCA3
8 pulmonary hypertension 29.1 SFTPC GJB2 ABCA3
9 choreoathetosis and congenital hypothyroidism with or without pulmonary dysfunction 11.7
10 bronchopulmonary dysplasia 10.7
11 patent ductus arteriosus 1 10.6
12 pneumothorax 10.5
13 pre-eclampsia 10.3
14 gestational diabetes 10.2
15 respiratory failure 10.2
16 disseminated intravascular coagulation 10.2
17 pulmonary edema 10.2
18 exudative vitreoretinopathy 1 10.2
19 enterocolitis 10.2
20 pneumonia 10.2
21 perinatal necrotizing enterocolitis 10.2
22 otitis media 10.1
23 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
24 preterm premature rupture of the membranes 10.1
25 funisitis 10.1
26 intrahepatic cholestasis of pregnancy 10.1
27 cerebral palsy 10.1
28 cervical incompetence 10.1
29 chorioamnionitis 10.1
30 metabolic acidosis 10.1
31 placenta praevia 10.1
32 asphyxia neonatorum 10.1
33 kernicterus 10.1
34 bacterial pneumonia 10.1
35 placental abruption 10.1
36 48,xyyy 10.1
37 oligohydramnios 10.0
38 surfactant metabolism dysfunction, pulmonary, 1 10.0 SFTPC ABCA3
39 lipid pneumonia 10.0 SFTPC ABCA3
40 leigh syndrome 10.0
41 pyruvate kinase deficiency of red cells 10.0
42 sudden infant death syndrome 10.0
43 allergic rhinitis 10.0
44 antithrombin iii deficiency 10.0
45 cyanosis, transient neonatal 10.0
46 allergic disease 10.0
47 goiter 10.0
48 diarrhea 10.0
49 rhinitis 10.0
50 congestive heart failure 10.0

Graphical network of the top 20 diseases related to Respiratory Distress Syndrome, Infant:

Diseases related to Respiratory Distress Syndrome, Infant

Symptoms & Phenotypes for Respiratory Distress Syndrome, Infant

UMLS symptoms related to Respiratory Distress Syndrome, Infant:

dyspnea, hemoptysis, apnea, respiratory distress, cheyne-stokes respiration, coughing, hoarseness

MGI Mouse Phenotypes related to Respiratory Distress Syndrome, Infant:

# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.02 ABCA3 ABCC8 BRAF GJB2 SFTPC

Drugs & Therapeutics for Respiratory Distress Syndrome, Infant

Drugs for Respiratory Distress Syndrome, Infant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 332)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Beractant Approved Phase 4 108778-82-1
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Racepinephrine Approved Phase 4 329-65-7 838
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
Cisatracurium Approved Phase 4 96946-41-7 62887
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Ibuprofen Approved Phase 4 15687-27-1 3672
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
18 Poractant alfa Approved Phase 4 129069-19-8
Remifentanil Approved Phase 4 132875-61-7 60815
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Budesonide Approved Phase 4 51333-22-3 63006 5281004
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7 5280489
26 Carotenoids Phase 4
Picolinic acid Phase 4 98-98-6 1018
28 Provitamins Phase 4
29 Chelating Agents Phase 4
30 Iron Chelating Agents Phase 4
31 Adrenergic alpha-Agonists Phase 4
32 Hydrocortisone 17-butyrate 21-propionate Phase 4
33 Hydrocortisone hemisuccinate Phase 4
34 Epinephryl borate Phase 4
35 Cholinergic Antagonists Phase 4
36 Cholinergic Agents Phase 4
37 Neuromuscular Blocking Agents Phase 4
38 Psychotropic Drugs Phase 4
39 GABA Modulators Phase 4
40 Anti-Anxiety Agents Phase 4
41 Neuromuscular Nondepolarizing Agents Phase 4
42 Anesthetics Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Anesthetics, Intravenous Phase 4
45 Anesthetics, Dissociative Phase 4
46 Anesthetics, General Phase 4
47 Hypnotics and Sedatives Phase 4
48 Angiotensin Receptor Antagonists Phase 4
49 Anesthetics, Inhalation Phase 4
50 Angiotensin II Type 1 Receptor Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 928)
# Name Status NCT ID Phase Drugs
1 Efficacy Evaluation of Surfactant Administration for Respiratory Distress Syndrome Treatment Via Laryngeal Mask Airway. A Randomized Controlled Trial Unknown status NCT01173237 Phase 4
2 Efficacy of Rescue Surfactant Delivery Via Endotracheal Intubation (INSURE Technique) Versus Laryngeal Mask Airway (LMA) for Respiratory Distress Syndrome (RDS) in Preterm Neonates Unknown status NCT02164734 Phase 4 remifentanil
3 The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Unknown status NCT03366584 Phase 4 Dexamethasone
4 Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI) Unknown status NCT00368680 Phase 4
5 Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT01763853 Phase 4 4% albumin
6 Comparative Trial of Two Strategies of RDS Treatment in Newborns With Birth Weight > 1500 Grams Unknown status NCT00277030 Phase 4 Surfactant
7 Sleep Intervention During Acute Lung Injury Unknown status NCT01050699 Phase 4 Dexmedetomidine;Midazolam and Fentanyl
8 Effect of Treatment With Stress-Doses Glucocorticoid on Mortality in Patients With ARDS and Relative Adrenal Insufficiency Unknown status NCT00773058 Phase 4 hydrocortisone;placebo
10 Prevention of Chronic Lung Disease (CLD) in Preterm Infants -A New Therapeutic Regimen Unknown status NCT00883532 Phase 4 budesonide;surfactant and air (placebo)
11 Propofol and Remifentanil Versus Midazolam and Remifentanil as Premedication Allowing Very Early Extubation After Surfactant Treatment in Preterm Neonates With Respiratory Distress Syndrome Unknown status NCT00797160 Phase 4 propofol
12 Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study Unknown status NCT03275415 Phase 4 budesonide;Saline
13 Effects of NMBA on the Alteration of Transpulmonary Pressures at the Early Phase of ARDS Unknown status NCT01573715 Phase 4 NIMBEX;NIMBEX
14 The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study Unknown status NCT02978976 Phase 4 Betamethasone;saline
15 Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant Completed NCT01941524 Phase 4 Poractant alfa instillation;Beractant instillation
16 Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation Completed NCT01042600 Phase 4
17 Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress Completed NCT00486850 Phase 4
18 An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome Completed NCT00501982 Phase 4 Poractant alfa (Curosurf®)
19 Effects of Bolus Surfactant Therapy on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants With Severe Respiratory Distress Syndrome Completed NCT01923844 Phase 4 exogenous surfactant
20 Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study. Completed NCT02166853 Phase 4 sevoflurane;midazolam
21 Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants Completed NCT01741129 Phase 4
22 Corticosteroid Mediates Acute Respiratory Distress Syndrome Via NLRP3 Inflammasome Signaling Pathway Completed NCT02819453 Phase 4 Methylprednisolone
23 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone
24 Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS) Completed NCT00391105 Phase 4 Remifentanil
25 Premedication for Non-Emergency Endotracheal Intubation In the NICU Completed NCT01749501 Phase 4 Rocuronium
26 Effects Of A Recruitment Maneuver On Plasma Levels of sRAGE, The Soluble Form of The Receptor For Advanced Glycation End Products, In Patients With Diffuse Acute Respiratory Distress Syndrome (ARDS) Completed NCT01600651 Phase 4
27 The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients Completed NCT03337373 Phase 4 cisatracurium
28 PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease Recruiting NCT04335786 Phase 4 Valsartan (Diovan);Placebo oral tablet
29 Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection Recruiting NCT04359862 Phase 4 Sevoflurane;Propofol
30 Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial Recruiting NCT04334629 Phase 4 Ibuprofen
31 Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome. Recruiting NCT03521063 Phase 4 Budesonide;Poractant Alfa;Saline
32 Premedication for Less Invasive Surfactant Administration Recruiting NCT03735563 Phase 4 Ketamine;Fentanyl
33 Effect of Inhalation Sedation With Sevoflurane Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome (ARDS) Course. Recruiting NCT04014218 Phase 4 Inhalation Sedation;Intravenous Sedation
34 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
35 Exogenous Surfactant in Very Preterm Neonates Presenting With Severe Respiratory Distress in Prevention of Bronchopulmonary Dysplasia Active, not recruiting NCT01039285 Phase 4 Curosurf
36 The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients Not yet recruiting NCT04345887 Phase 4 Spironolactone 100mg;Placebo oral tablet
37 Comparison of Two Fraction Oxygen Inspired (FiO2) Thresholds for the Surfactant Administration in Preterm Infants With Respiratory Disease Syndrome: a Single-center Randomized Phase IV Clinical Trial Not yet recruiting NCT04199364 Phase 4 Poractant Alfa 80 mg/mL Intratracheal Suspension
38 Stress Assessment in Preterm Infants With Respiratory Distress Syndrome Treated or Not With an Analgesic Drug During the Traditional or the Less Invasive Method of Surfactant Therapy. Not yet recruiting NCT04073173 Phase 4 Analgesic, Opioid
39 Effects of Adding L-Carnitine With Dexamethasone on Respiratory Distress Syndrome Development in Preterm Infants Suspended NCT03630367 Phase 4 Dexamethasone;L-Carnitine 1G/5mL Injection
40 Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 Terminated NCT04325061 Phase 4 Dexamethasone
41 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
42 Randomized Trial on Efficacy and Safety of the Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth (ACG Trial) Terminated NCT00295464 Phase 4 Betamethasone sodium phos (drug)
43 Cytokine Change in Bronchoalveolar Lavage Fluid After Early Budesonide-Surfactant Treatment in Premature Infants Terminated NCT00146497 Phase 4 Budesonide-Surfactant
44 Randomized Study Comparing the ASV to Conventional Ventilation for Intubated Patients During Inter-hospital Transfers. Controlled Randomized Monocentric Prospective Study Comparing ASV Versus Conventional Ventilation Modes Terminated NCT02348047 Phase 4
45 Pre Hospital Evaluation of Video Laryngoscopy : a Comparative Study of Macintosh and GLIDESCOPE Ranger® Withdrawn NCT01374061 Phase 4
46 Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome Unknown status NCT01265589 Phase 3 surfactant;surfactant+vitamin A
47 Liberal Oxygenation Versus Conservative Oxygenation in Patients With Acute Respiratory Distress Syndrome : Impact on Mortality (LOCO2 Study) Unknown status NCT02713451 Phase 3 Modulation of Inspired Fraction of Oxygen (FiO2)
48 Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial Unknown status NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta
49 A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients Unknown status NCT00465374 Phase 3
50 Intranasal Midazolam Versus Intranasal Ketamine to Sedate Newborns for Intubation in Delivery Room. Unknown status NCT01517828 Phase 3 Sedation by ketamine;Sedation with Midazolam

Search NIH Clinical Center for Respiratory Distress Syndrome, Infant

Inferred drug relations via UMLS 71 / NDF-RT 51 :

Albumin Human, USP
colfosceril palmitate
Nitric Oxide
Poractant alfa

Genetic Tests for Respiratory Distress Syndrome, Infant

Anatomical Context for Respiratory Distress Syndrome, Infant

MalaCards organs/tissues related to Respiratory Distress Syndrome, Infant:

Lung, Bone Marrow, Bone, Neutrophil, Fetal Lung, Heart, Liver

Publications for Respiratory Distress Syndrome, Infant

Articles related to Respiratory Distress Syndrome, Infant:

(show top 50) (show all 81)
# Title Authors PMID Year
Anterior placenta previa in the mid-trimester of pregnancy as a risk factor for neonatal respiratory distress syndrome. 61
30388184 2018
Cytokine profiles at birth and the risk of developing severe respiratory distress and chronic lung disease. 61
28616049 2017
The Haplotype TGGAG in the ABCA3 Gene Increases the Risk of Respiratory Distress Syndrome in Preterm Infants in Southern China. 61
26522252 2016
[Clinical features, prevention and treatment of respiratory distress syndrome in neonates of different gestational ages in tertiary hospitals in Northwest China]. 61
26483220 2015
[Epidemiological survey of neonatal respiratory distress syndrome in part of northwest regions in China]. 61
26080663 2015
[A multicenter study on the surfactant treatment in late-preterm or term infants with respiratory distress syndrome]. 61
25537535 2014
Heliox non-invasive ventilation for preventing extubation failure in preterm infants. 61
23145834 2013
Relationship between respiratory impedance and positive end-expiratory pressure in mechanically ventilated neonates. 61
23306585 2013
Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. 61
23166334 2012
Impact of volume guarantee on synchronized ventilation in preterm infants: a randomized controlled trial. 61
22618094 2012
Expression of SP-C and Ki67 in lungs of preterm infants dying from respiratory distress syndrome. 61
23027351 2012
Frequency Modulation and Spatiotemporal Stability of the sCPG in Preterm Infants with RDS. 61
22888359 2012
Early postnatal surge of serum Clara cell secretory protein in newborn infants. 61
21952535 2012
Physical and physicochemical factors effecting transport of chlorohydrocarbon gases from lung alveolar air to blood as measured by the causation of narcosis. 61
22458856 2012
Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome: preliminary results. 61
21781003 2011
Endothelin-1 and L-arginine in preterm infants with respiratory distress. 61
20700864 2011
Current status of neonatal acute respiratory disorders: a one-year prospective survey from a Chinese neonatal network. 61
21034580 2010
Surfactant administration for neonatal respiratory distress does not improve lung interstitial fluid clearance: echographic and experimental evidence. 61
20629494 2010
Pulmonary secretory phospholipase A2 in infants with respiratory distress syndrome stimulates in vitro neutrophil migration. 61
19478531 2010
[Retrospective analysis of elective caesarean section and respiratory distress syndrome in the term neonates]. 61
20021786 2009
Activation of T cells in preterm infants with respiratory distress syndrome. 61
19468239 2009
Respiratory Distress Syndrome Degrades the Fine Structure of the Non-Nutritive Suck In Preterm Infants. 61
19122873 2008
Free carnitine levels in respiratory distress syndrome during the first week of life. 61
17009198 2006
Evaluation of serum cortisol levels in a relatively large and mature group of ventilated and nonventilated preterm infants with respiratory distress syndrome. 61
16841278 2006
Cerebral oxygenation and cerebral oxygen extraction in the preterm infant: the impact of respiratory distress syndrome. 61
16506004 2006
A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. 61
16188788 2005
Is carbon monoxide-mediated cyclic guanosine monophosphate production responsible for low blood pressure in neonatal respiratory distress syndrome? 61
15516362 2005
Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. 61
15650304 2005
Population based study on the outcome of small for gestational age newborns. 61
15613577 2005
[Mortality risk factors in premature infants with respiratory distress syndrome treated by mechanical ventilation]. 61
16053172 2005
Exhaled nitric oxide and tracheal endothelin-1 in preterm infants with and without RDS. 61
14520725 2003
Surfactant protein A and B genetic variants in respiratory distress syndrome in singletons and twins. 61
12947025 2003
Lung epithelial cells undergo apoptosis in neonatal respiratory distress syndrome. 61
12538783 2003
Prediction of respiratory distress syndrome using the Abbott FLM-II amniotic fluid assay. 61
12417097 2002
Cord serum lipid and apolipoprotein levels in preterm infants with the neonatal respiratory distress syndrome. 61
12375541 2002
Tracheobronchial aspirate fluid neutrophil lipocalin, elastase- and neutrophil protease-4-alpha1-antitrypsin complexes, protease inhibitors and free proteolytic activity in respiratory distress syndrome. 61
12412868 2002
Nitric oxide production and plasma cyclic guanosine monophosphate in premature infants with respiratory distress syndrome. 61
12373064 2002
Epidermal growth factor in the lungs of infants developing chronic lung disease. 61
11757630 2001
A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. 61
11433048 2001
Study of plasma endothelin-1 concentrations in Taiwanese neonates with respiratory distress. 61
11413881 2001
Elevated type IV collagen in bronchoalveolar lavage fluid from infants with bronchopulmonary dysplasia. 61
11150828 2001
Surfactant proteins A and B as interactive genetic determinants of neonatal respiratory distress syndrome. 61
11063734 2000
Effect of patent ductus arteriosus and indomethacin treatment on serum cardiac troponin T levels in preterm infants with respiratory distress syndrome. 61
10789933 2000
Chronic lung disease in extremely low birth weight infants: a two-year retrospective analysis. 61
10927943 2000
Randomized controlled trial of volume-targeted synchronized ventilation and conventional intermittent mandatory ventilation following initial exogenous surfactant therapy. 61
10613781 2000
Measurement of protein flux with positron emission tomography in neonates. 61
10325807 1999
Neonatal lung function in very immature infants with and without RDS. 61
10642959 1999
A prospective randomized comparison of conventional mechanical ventilation and very early high frequency oscillatory ventilation in extremely premature newborns with respiratory distress syndrome. 61
10051081 1999
Indications of coagulation and/or fibrinolytic system activation in healthy and sick very-low-birth-weight neonates. 61
9742262 1998
A survey on the treatment strategy of patent ductus arteriosus in very low-birth-weight infants. 61
9553290 1998

Variations for Respiratory Distress Syndrome, Infant

ClinVar genetic disease variations for Respiratory Distress Syndrome, Infant:

# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCA3 NM_001089.3(ABCA3):c.614-2A>G SNV Likely pathogenic 598980 rs773223403 16:2369843-2369843 16:2319842-2319842
2 BRAF NM_001374258.1(BRAF):c.1622A>G (p.Glu541Gly) SNV Likely pathogenic 13978 rs180177039 7:140477806-140477806 7:140778006-140778006
3 SFTPC NM_001317778.2(SFTPC):c.163C>T (p.Leu55Phe) SNV Likely pathogenic 598978 rs1563221666 8:22020207-22020207 8:22162694-22162694
4 GJB2 NM_004004.6(GJB2):c.488T>C (p.Met163Thr) SNV Likely pathogenic 449488 rs1273330603 13:20763233-20763233 13:20189094-20189094
5 ABCC8 NM_000352.6(ABCC8):c.1793G>A (p.Arg598Gln) SNV Likely pathogenic 523361 rs1344172059 11:17452385-17452385 11:17430838-17430838
6 ABCC8 NM_000352.6(ABCC8):c.3517G>A (p.Val1173Met) SNV Likely pathogenic 35609 rs141322087 11:17426099-17426099 11:17404552-17404552
7 DES NM_001927.4(DES):c.407T>A (p.Leu136His) SNV Uncertain significance 44261 rs397516695 2:220283591-220283591 2:219418869-219418869
8 ABCA3 NM_001089.3(ABCA3):c.3200G>A (p.Gly1067Glu) SNV Uncertain significance 598979 rs1567339065 16:2336773-2336773 16:2286772-2286772

Expression for Respiratory Distress Syndrome, Infant

Search GEO for disease gene expression data for Respiratory Distress Syndrome, Infant.

Pathways for Respiratory Distress Syndrome, Infant

Pathways related to Respiratory Distress Syndrome, Infant according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways

GO Terms for Respiratory Distress Syndrome, Infant

Cellular components related to Respiratory Distress Syndrome, Infant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 8.96 GJB2 BRAF
2 alveolar lamellar body GO:0097208 8.62 SFTPC ABCA3

Biological processes related to Respiratory Distress Syndrome, Infant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.33 GJB2 ABCC8 ABCA3
2 response to lipopolysaccharide GO:0032496 9.26 GJB2 ABCC8
3 female pregnancy GO:0007565 8.96 GJB2 ABCC8
4 visual learning GO:0008542 8.62 BRAF ABCC8

Molecular functions related to Respiratory Distress Syndrome, Infant according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 8.62 ABCC8 ABCA3

Sources for Respiratory Distress Syndrome, Infant

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....